StockMirror — Stock Screener

ACI Q4 FY26 Results & Earnings Analysis

Sentiment: Neutral (Confidence: medium)

Earnings Summary

Archean Chemical reported a challenging Q4 FY26 with 9% YoY revenue decline and 34.3% YoY EBITDA decline due to multiple headwinds: U.S.-Iran conflict, Kutch road construction, and sharp cost inflation. However, bromine production recovered to historical levels, allowing for upward contract renegotiations. The semiconductor project achieved a critical milestone (FSA signing). The near-term outlook is cautious with H1 FY27 expected to remain lean, but H2 recovery is anticipated. Long-term growth targets remain intact, but execution in derivatives and cost normalization are key watch areas.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management outlined three strategic priorities: consolidate core salt/bromine, scale derivatives, and invest in long-term opportunities (semiconductors, batteries). They emphasize driving earnings quality and effective capital allocation, balancing volume growth with margin recovery.

About Archean Chemical Industries Limited

Archean Chemical Industries Limited (ACI) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More